Potent triazolothione inhibitor of heat-shock protein-90

Chemical Biology and Drug Design

Volumn 74, Issue 1, 2009, Pages 43-50

  Feldman, Richard I ^a   Mintzer, Bob ^a   Zhu, Daguang ^a   Wu, James M ^a   Biroc, Sandra L ^a   Yuan, Shendong ^a   Emayan, Kumar ^a   Chang, Zheng ^a   Chen, Deborah ^a   Arnaiz, Damian O ^a   Bryant, Judi ^a   Ge, Xue Snow ^a   Whitlow, Marc ^a   Adler, Marc ^a   Polokoff, Mark A ^a   Li, Wei Wei ^a   Ferrer, Mike ^a   Sato, Takashi ^a   Gu, Jian Ming ^a   Shen, Jun ^a   Tseng, Jih Lie ^a   Dinter, Harald ^a   Buckman, Brad ^a   more..

^a BAYER CORPORATION   (United States)

Author keywords

Heat shock; Hsp90; Inhibitor; Small molecule; Triazolothione

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BX 2819; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; RADICICOL; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SINGLE DRUG DOSE; STOMACH CARCINOMA;

ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 67650468165     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00833.x     Document Type: Article

References (29)

1. Pearl L.H., Prodromou C., Workman P. (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 410 : 439 453.
2. Messaoudi S., Peyrat J.F., Brion J.D., Alami M. (2008) Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 8 : 761 782.
3. Solit D.B., Chiosis G. (2008) Development and application of Hsp90 inhibitors. Drug Discov Today 13 : 38 43.
4. Burrows F., Zhang H., Kamal A. (2004) Hsp90 activation and cell cycle regulation. Cell Cycle 3 : 1530 1536. (Pubitemid 40521406)
5. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91 : 8324 8328.
6. Sharp S., Workman P. (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95 : 323 348. (Pubitemid 44088424)
7. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., Cropp G.F., Johnson R.G., Hannah A.L., Hudis C.A. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25 : 5410 5417. (Pubitemid 350232217)
8. Pacey S., Banerji U., Judson I., Workman P. (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172 : 331 358.
9. Weigel B.J., Blaney S.M., Reid J.M., Safgren S.L., Bagatell R., Kersey J., Neglia J.P., Ivy S.P., Ingle A.M., Whitesell L., Gilbertson R.J., Krailo M., Ames M., Adamson P.C. (2007) A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 13 : 1789 1793. (Pubitemid 46952947)
10. Llauger L., He H., Kim J., Aguirre J., Rosen N., Peters U., Davies P., Chiosis G. (2005) Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 48 : 2892 2905. (Pubitemid 40548103)
11. Llauger-Bufi L., Felts S.J., Huezo H., Rosen N., Chiosis G. (2003) Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett 13 : 3975 3978. (Pubitemid 37338430)
12. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 : 239 250. (Pubitemid 27199896)
13. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., Neckers L.M. (1998) Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 3 : 100 108. (Pubitemid 28327422)
14. Agatsuma T., Ogawa H., Akasaka K., Asai A., Yamashita Y., Mizukami T., Akinaga S., Saitoh Y. (2002) Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem 10 : 3445 3454.
15. Cheung K.M., Matthews T.P., James K., Rowlands M.G., Boxall K.J., Sharp S.Y., Maloney A., Roe S.M., Prodromou C., Pearl L.H., Aherne G.W., McDonald E., Workman P. (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 15 : 3338 3343. (Pubitemid 40835731)
16. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.M. et al. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51 : 196 218.
17. Morimoto R.I. (1998) Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 12 : 3788 3796. (Pubitemid 29024840)
18. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42 : 260 266. (Pubitemid 29069861)
19. Kreusch A., Han S., Brinker A., Zhou V., Choi H.S., He Y., Lesley S.A., Caldwell J., Gu X.J. (2005) Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg Med Chem Lett 15 : 1475 1478. (Pubitemid 40269014)
20. Dymock B.W., Barril X., Brough P.A., Cansfield J.E., Massey A., McDonald E., Hubbard R.E., Surgenor A., Roughley S.D., Webb P., Workman P., Wright L., Drysdale M.J. (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48 : 4212 4215. (Pubitemid 40884922)
21. Barril X., Brough P., Drysdale M., Hubbard R.E., Massey A., Surgenor A., Wright L. (2005) Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 15 : 5187 5191. (Pubitemid 41463644)
22. Obermann W.M., Sondermann H., Russo A.A., Pavletich N.P., Hartl F.U. (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143 : 901 910. (Pubitemid 28547391)
23. Shinomiya N., Gao C.F., Xie Q., Gustafson M., Waters D.J., Zhang Y.W., Vande Woude G.F. (2004) RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 64 : 7962 7970. (Pubitemid 39446930)
24. Bellon S.F., Kaplan-Lefko P., Yang Y., Zhang Y., Moriguchi J., Rex K., Johnson C.W. et al. (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 283 : 2675 2683.
25. He H., Zatorska D., Kim J., Aguirre J., Llauger L., She Y., Wu N., Immormino R.M., Gewirth D.T., Chiosis G. (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem 49 : 381 390. (Pubitemid 43077351)
26. Eiseman J.L., Lan J., Lagattuta T.F., Hamburger D.R., Joseph E., Covey J.M., Egorin M.J. (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55 : 21 32.
27. Banerji U., Walton M., Raynaud F., Grimshaw R., Kelland L., Valenti M., Judson I., Workman P. (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11 : 7023 7032. (Pubitemid 41428762)
28. Chiosis G., Neckers L. (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 1 : 279 284.
29. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 : 407 410. (Pubitemid 37187270)